相似文献
1
High-dose low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial).
Eur Respir J. 2022 Feb 17;59(2). doi: 10.1183/13993003.02930-2021. Print 2022 Feb.
2
Persistence of post-COVID lung parenchymal abnormalities during the three-month follow-up.
Adv Respir Med. 2021;89(5):477-483. doi: 10.5603/ARM.a2021.0090. Epub 2021 Oct 6.
3
Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.
Lancet Respir Med. 2021 Mar;9(3):275-284. doi: 10.1016/S2213-2600(20)30558-0. Epub 2021 Jan 7.
4
Clinical characteristics, symptoms and outcomes of 1054 adults presenting to hospital with suspected COVID-19: A comparison of patients with and without SARS-CoV-2 infection.
J Infect. 2020 Dec;81(6):937-943. doi: 10.1016/j.jinf.2020.09.033. Epub 2020 Sep 28.
5
A prospective, randomized, controlled study assessing vagus nerve stimulation using the gammaCore®-Sapphire device for patients with moderate to severe CoViD-19 Respiratory Symptoms (SAVIOR): A structured summary of a study protocol for a randomised controlled trial".
Trials. 2020 Jun 26;21(1):576. doi: 10.1186/s13063-020-04486-w.
6
Effect of early treatment with polyvalent immunoglobulin on acute respiratory distress syndrome associated with SARS-CoV-2 infections (ICAR trial): study protocol for a randomized controlled trial.
Trials. 2021 Feb 28;22(1):170. doi: 10.1186/s13063-021-05118-7.
7
Role of the early short-course corticosteroids treatment in ARDS caused by COVID-19: A single-center, retrospective analysis.
Adv Med Sci. 2021 Sep;66(2):262-268. doi: 10.1016/j.advms.2021.04.002. Epub 2021 Apr 24.
8
Pathogenesis-directed therapy of 2019 novel coronavirus disease.
J Med Virol. 2021 Mar;93(3):1320-1342. doi: 10.1002/jmv.26610. Epub 2020 Nov 10.
引用本文的文献
1
Organizing pneumonia in hospitalized COVID-19 patients: risk factors and long-term outcomes.
Pneumonia (Nathan). 2025 Jul 5;17(1):18. doi: 10.1186/s41479-025-00169-9.
2
Long-Term Lung Sequelae in Survivors of Severe/Critical COVID-19 Pneumonia: The "Non-Steroid", "Non-Interventional" Approach.
J Clin Med. 2025 Jan 8;14(2):347. doi: 10.3390/jcm14020347.
3
Trans-bronchial forceps biopsy for COVID-19 related diffuse parenchymal lung abnormalities.
BMC Pulm Med. 2024 Dec 23;24(1):631. doi: 10.1186/s12890-024-03449-0.
4
Multidisciplinary Management Strategies for Long COVID: A Narrative Review.
Cureus. 2024 May 1;16(5):e59478. doi: 10.7759/cureus.59478. eCollection 2024 May.
5
The effectiveness of glucocorticoid treatment in post-COVID-19 pulmonary involvement.
Pneumonia (Nathan). 2024 Feb 5;16(1):2. doi: 10.1186/s41479-023-00123-7.
6
The clinical, functional, and radiological effect of long-term used immunosuppressive therapy for post-COVID-19 interstitial lung disease.
Sarcoidosis Vasc Diffuse Lung Dis. 2023 Dec 20;40(4):e2023049. doi: 10.36141/svdld.v40i4.15055.
7
Post-COVID-19 pulmonary fibrosis: An ongoing concern.
Ann Thorac Med. 2023 Oct-Dec;18(4):173-181. doi: 10.4103/atm.atm_7_23. Epub 2023 Oct 17.
8
A case series of three patients with histologically proven post COVID-19 organizing pneumonia.
Respirol Case Rep. 2023 Sep 26;11(10):e01229. doi: 10.1002/rcr2.1229. eCollection 2023 Oct.
9
Pulmonary Sequelae of COVID-19: Focus on Interstitial Lung Disease.
Cells. 2023 Sep 8;12(18):2238. doi: 10.3390/cells12182238.
10
Risk factors for the development of interstitial lung disease following severe COVID-19 pneumonia and outcomes of systemic corticosteroid therapy: 3-month follow-up.
Sarcoidosis Vasc Diffuse Lung Dis. 2023 Sep 13;40(3):e2023029. doi: 10.36141/svdld.v40i3.14418.
本文引用的文献
1
Adjunctive corticosteroid treatment for organizing pneumonia in COVID-19 patients with persistent respiratory failure.
Respir Med. 2021 Oct;187:106571. doi: 10.1016/j.rmed.2021.106571. Epub 2021 Aug 10.
2
A prolonged steroid therapy may be beneficial in some patients after the COVID-19 pneumonia.
Eur Clin Respir J. 2021 Jun 24;8(1):1945186. doi: 10.1080/20018525.2021.1945186.
3
The Conundrum of 'Long-COVID-19': A Narrative Review.
Int J Gen Med. 2021 Jun 14;14:2491-2506. doi: 10.2147/IJGM.S316708. eCollection 2021.
4
Swiss Recommendations for the Follow-Up and Treatment of Pulmonary Long COVID.
Respiration. 2021;100(8):826-841. doi: 10.1159/000517255. Epub 2021 Jun 4.
5
3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study.
Lancet Respir Med. 2021 Jul;9(7):747-754. doi: 10.1016/S2213-2600(21)00174-0. Epub 2021 May 5.
6
Multidisciplinary approach for post-acute COVID-19 syndrome: time to break down the walls.
Eur Respir J. 2021 Jul 8;58(1). doi: 10.1183/13993003.01090-2021. Print 2021 Jul.
7
Pulmonary Function and Radiologic Features in Survivors of Critical COVID-19: A 3-Month Prospective Cohort.
Chest. 2021 Jul;160(1):187-198. doi: 10.1016/j.chest.2021.02.062. Epub 2021 Mar 4.
8
Persistent Post-COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment.
Ann Am Thorac Soc. 2021 May;18(5):799-806. doi: 10.1513/AnnalsATS.202008-1002OC.
9
A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations.
Thorax. 2021 Apr;76(4):402-404. doi: 10.1136/thoraxjnl-2020-216308. Epub 2020 Dec 3.
10
A 12-week combination of clarithromycin and prednisone compared to a 24-week prednisone alone treatment in cryptogenic and radiation-induced organizing pneumonia.
Sarcoidosis Vasc Diffuse Lung Dis. 2018;35(3):230-238. doi: 10.36141/svdld.v35i3.6547. Epub 2018 Apr 28.
Zotero 插件